https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-16 / Oncotarget 2017 05;8(20):33897-33910
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-16 / Oncotarget 2017 05;8(20):33897-339102017-05-16 00:00:002019-02-15 08:47:54Immunotherapeutic approaches for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-13 / Oncotarget 2017 Aug;8(32):52651-52664
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-13 / Oncotarget 2017 Aug;8(32):52651-526642017-04-13 00:00:002017-04-13 00:00:00Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-22 / J Transl Med 2017 03;15(1):64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-22 / J Transl Med 2017 03;15(1):642017-03-22 00:00:002019-02-15 08:47:53Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-27 / Eur. J. Pharmacol. 2017 May;802:85-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-27 / Eur. J. Pharmacol. 2017 May;802:85-922017-02-27 00:00:002019-02-15 09:13:32Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-07 / Int J Hyperthermia 2016 09;32(6):648-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-07 / Int J Hyperthermia 2016 09;32(6):648-562016-06-07 00:00:002019-03-27 11:35:26Electro-hyperthermia up-regulates tumour suppressor Septin 4 to induce apoptotic cell death in hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-302016-04-27 00:00:002019-02-15 09:13:31Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-15 / Hepatology 2016 08;64(2):456-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-15 / Hepatology 2016 08;64(2):456-722016-04-15 00:00:002016-04-15 00:00:00Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-07 / Tumour Biol. 2016 Aug;37(8):11267-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-07 / Tumour Biol. 2016 Aug;37(8):11267-782016-03-07 00:00:002019-02-15 08:47:52Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-07 / World J. Gastroenterol. 2016 Jan;22(1):253-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-07 / World J. Gastroenterol. 2016 Jan;22(1):253-612016-01-07 00:00:002019-02-15 08:47:51Current status and perspectives of immune-based therapies for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-10 / Br. J. Cancer 2015 Dec;113(12):1666-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-10 / Br. J. Cancer 2015 Dec;113(12):1666-762015-12-10 00:00:002019-02-15 08:47:50A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
